OpGen

OpGen Debt

The Debt of OpGen (OPGN) as of Oct 27, 2026 is 1.85 M USD. In the previous year, Debt was 13.04 M USD — a change of -85.83% (lower).

Debt

1.85 MUSD

YoY

-85.83%

Last updated:

In 2025, OpGen's total debt was 1.85 M USD, a -85.83% change from the 13.04 M USD total debt recorded in the previous year.

The OpGen Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
1.30 M USD
Jan 1, 2018
1.90 M USD
Jan 1, 2019
4.76 M USD
Jan 1, 2020
22.85 M USD
Jan 1, 2021
25.18 M USD
Jan 1, 2022
14.84 M USD
Jan 1, 2023
13.04 M USD
Jan 1, 2025
1.85 M USD
The OpGen Debt history
YEARDebtYoY
1.85 MUSD-85.83%
13.04 MUSD-12.10%
14.84 MUSD-41.07%
25.18 MUSD+10.20%
22.85 MUSD+380.36%
4.76 MUSD+150.94%
1.90 MUSD+46.26%
1.30 MUSD-4.34%
1.35 MUSD-16.87%
1.63 MUSD-49.69%
3.24 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Debt Details

Understanding OpGen's Debt Structure

OpGen's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing OpGen's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to OpGen’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in OpGen’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about OpGen stock

Debt of OpGen is 1.85 M USD in 2025.

Debt of OpGen changed from 13.04 M USD to 1.85 M USD, representing a -85.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt OpGen since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — OpGen

All Key Metrics — OpGen